Floatz logo

FULVESTRANT

CCNE1 Amplification

Avenzo Therapeutics, Inc.Small moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the CCNE1 Amplification cohort.

Asset / SponsorPhaseRating
Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Letrozole
Avenzo Therapeutics, Inc.
Phase 1/2CCC
LEUPROLIDE
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Zoladex
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Carboplatin
Avenzo Therapeutics, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

FULVESTRANT is also rated in:

Hormone Receptor Positive TumorDormant
BB
Indicative ·
70 / 100
View asset →
hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →